Koutsogiannaki Sophia, Shimaoka Motomu, Yuki Koichi
Department of Anaesthesia, Harvard Medical School, Boston, Massachusetts, USA.
Department of Anesthesiology, Critical Care and Pain Medicine, Cardiac Anesthesia Division, Boston Children's Hospital, Boston, Massachusetts, USA.
Transl Perioper Pain Med. 2019;6(2):27-38. doi: 10.31480/2330-4871/084. Epub 2019 Feb 21.
Acute respiratory distress syndrome (ARDS) remains to pose a high morbidity and mortality without any targeted therapies. Sedation, usually given intravenously, is an important part of clinical practice in intensive care unit (ICU), and the effect of sedatives on patients' outcomes has been studied intensively. Although volatile anesthetics are not routine sedatives in ICU, preclinical and clinical studies suggested their potential benefit in pulmonary pathophysiology. This review will summarize the current knowledge of ARDS and the role of volatile anesthetic sedation in this setting from both clinical and mechanistic standpoints. In addition, we will review the infrastructure to use volatile anesthetics.
急性呼吸窘迫综合征（ARDS）在没有任何针对性治疗的情况下，发病率和死亡率仍然很高。镇静通常通过静脉给药，是重症监护病房（ICU）临床实践的重要组成部分，并且已经对镇静剂对患者预后的影响进行了深入研究。尽管挥发性麻醉剂不是ICU中的常规镇静剂，但临床前和临床研究表明它们在肺部病理生理学方面具有潜在益处。本综述将从临床和机制角度总结目前关于ARDS的知识以及挥发性麻醉剂镇静在这种情况下的作用。此外，我们还将综述使用挥发性麻醉剂的基础设施。
